Adial Pharmaceuticals Announces Reverse Stock Split to Regain Compliance with Nasdaq’s Minimum Bid Price Requirement

Core Viewpoint - Adial Pharmaceuticals will implement a 1-for-25 reverse stock split to comply with Nasdaq's minimum bid price requirement and enhance its capital markets profile, effective February 5, 2026 [1][3][4] Group 1: Reverse Stock Split Details - The reverse stock split will reduce the number of outstanding shares from approximately 27.8 million to about 1.1 million, while maintaining the ownership percentage of existing shareholders [2] - The new CUSIP number for the common stock post-split will be 00688A304, and trading on a split-adjusted basis will commence on February 6, 2026 [1][2] Group 2: Compliance and Market Strategy - The reverse split aims to ensure compliance with Nasdaq's requirement of a minimum bid price of $1.00 per share, making the stock more appealing to institutional and retail investors [3] - The company believes this action will strengthen its capital markets profile and create a more efficient public float, supporting broader investor interest [4] Group 3: Company Overview and Future Plans - Adial Pharmaceuticals is focused on developing treatments for addiction, with its lead product AD04 targeting Alcohol Use Disorder [5] - The company plans to conduct a new Phase 3 clinical trial for AD04, which has shown promising results in reducing drinking among heavy drinkers [5]